{
    "clinical_study": {
        "@rank": "6699", 
        "acronym": "MIMeRiC", 
        "arm_group": [
            {
                "arm_group_label": "MI and Medication review", 
                "arm_group_type": "Experimental", 
                "description": "The intervention starts three months post-discharge after the standard treatment at the out-patients clinic. A medication review focused on cardiovascular drugs, and a counselling session with a clinical pharmacist using Motivational Interviewing (MI)-approach, and a follow-up phone call two weeks later. For patients with negative beliefs about medicines, three additional MI-sessions in clinic or by phone are planned together with the patient. Irrespective of beliefs the intervention ends with a second medication review and counselling session, which is coordinated with the 12-months post-discharge follow-up in primary care."
            }, 
            {
                "arm_group_label": "Standard treatment", 
                "arm_group_type": "Active Comparator", 
                "description": "Standard treatment at the cardiology out-patient clinic. Follow-up by nurse after two weeks and by physician after two months."
            }
        ], 
        "brief_summary": {
            "textblock": "Low medication adherence in patients with coronary heart disease increases mortality.\n\n      This study investigates if an intervention of medication review and counselling can improve\n      patients' medication adherence and treatment results."
        }, 
        "brief_title": "Motivational Interviewing and Medication Review in Coronary Heart Disease", 
        "completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Coronary Heart Disease", 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease", 
                "Heart Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study will investigate the effects of medication review and Motivational Interviewing\n      (MI) on patients with Coronary Heart Disease (CHD). Clinical pharmacists competent in MI and\n      cardiology will conduct medication interviews and medication reviews at the outpatient\n      clinic. The intervention will continue during 9 months, with interviews and reviews as\n      needed.\n\n      Follow-up of results will take place 16 months after inclusion (corresponding to 4 months\n      after the end of intervention).\n\n      The MI-Component will be quality assured by MITI 3.1-coding (Motivational Interviewing\n      Treatment Integrity). The study will investigate effects on clinical outcomes, medication\n      adherence, patients\u00b4 beliefs about medicines, quality of life and health economics."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Admitted for angiography\n\n          -  Verified Coronary Artery Disease (ICD-10 I20-I21)\n\n          -  Planned for follow up at the out-patient clinic (standard treatment)\n\n          -  Swedish speaking\n\n        Exclusion Criteria:\n\n          -  Cognitive impairment or any othe condition making interview or phone calls\n             impossible."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "585", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 31, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02102503", 
            "org_study_id": "GLAS-1-2013"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "MI and Medication review", 
                    "Standard treatment"
                ], 
                "intervention_name": "Standard Treatment", 
                "intervention_type": "Behavioral"
            }, 
            {
                "arm_group_label": "MI and Medication review", 
                "intervention_name": "MI and Medication review", 
                "intervention_type": "Behavioral"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 2, 2014", 
        "link": {
            "description": "Ongoing projects at the eHealth Institute", 
            "url": "http://lnu.se/research-groups/the-ehealth-institute/projekt/projects/glas?l=en"
        }, 
        "location": {
            "contact": {
                "email": "malin.ostbringcarlsson@lnu.se", 
                "last_name": "Malin J \u00d6stbring, MSc Pharm", 
                "phone": "+4648084541"
            }, 
            "facility": {
                "address": {
                    "city": "Kalmar", 
                    "country": "Sweden", 
                    "zip": "39182"
                }, 
                "name": "Kalmar County Hospital"
            }, 
            "investigator": {
                "last_name": "Malin J \u00d6stbring, MSc Pharm", 
                "role": "Sub-Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Sweden"
        }, 
        "number_of_arms": "2", 
        "official_title": "Motivational Interviewing and Medication Review in the Secondary Prevention of Coronary Heart Disease", 
        "other_outcome": [
            {
                "description": "According to Medication Assessment Tool for secondary prevention of Coronary Heart disease", 
                "measure": "Quality of prescribing", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Beliefs about medicines questionnaire (BMQ-S10), categories: accepting, ambivalent, neutral, skeptical.", 
                "measure": "Beliefs about medicines - percent of patients per category", 
                "safety_issue": "No", 
                "time_frame": "16 months"
            }
        ], 
        "overall_contact": {
            "email": "malin.ostbringcarlsson@lnu.se", 
            "last_name": "Malin J Ostbring, MSc Pharm", 
            "phone": "+4648084541"
        }, 
        "overall_contact_backup": {
            "email": "lina.hellstrom@lnu.se", 
            "last_name": "Lina Hellstrom, PhD Pharm", 
            "phone": "+4648084793"
        }, 
        "overall_official": {
            "affiliation": "Linneaus University", 
            "last_name": "G\u00f6ran Petersson, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Sweden: Regional Ethical Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "According to Swedish guidelines the goal is < 1,8mmol/L or at least 50% reduction from baseline.", 
            "measure": "Percentage of patients who achieve the treatment goal for Low density lipoprotein cholesterol (LDL-C)", 
            "safety_issue": "No", 
            "time_frame": "16 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02102503"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Linneaus University", 
            "investigator_full_name": "G\u00f6ran Petersson", 
            "investigator_title": "Professor of Health Informatics with focus on Pharmaceutical Science", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Self-reported adherence according to Morisky-8-Item Adherence Scale", 
                "measure": "Percentage of patients adherent to cholesterol lowering treatment", 
                "safety_issue": "No", 
                "time_frame": "16 months"
            }, 
            {
                "description": "Prescription refill according to the Swedish Prescribed Drug Register, Percent Day Covered (PDC) 80% is set as the cut-off for adherence.", 
                "measure": "Percentage of patients adherent to cholesterol lowering treatment", 
                "safety_issue": "No", 
                "time_frame": "16 months"
            }, 
            {
                "description": "Prescription refill according to the Swedish Prescribed Drug Register, Percent Day Covered (PDC) 80% is set as the cut-off for adherence.", 
                "measure": "Percentage of patients adherent to preventive medication: Angiotensin Converter Enzyme inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB)", 
                "safety_issue": "No", 
                "time_frame": "16 months"
            }, 
            {
                "description": "Prescription refill according to the Swedish Prescribed Drug Register, Percent Day Covered (PDC) 80% is set as the cut-off for adherence.", 
                "measure": "Percentage of patients adherent to preventive medication: Acetylsalicylic acid (ASA)", 
                "safety_issue": "No", 
                "time_frame": "16 months"
            }, 
            {
                "description": "Prescription refill according to the Swedish Prescribed Drug Register, Percent Day Covered (PDC) 80% is set as the cut-off for adherence.", 
                "measure": "Percentage of patients adherent to preventive medication: P2Y12-antagonist", 
                "safety_issue": "No", 
                "time_frame": "16 months"
            }, 
            {
                "description": "Prescription refill according to the Swedish Prescribed Drug Register, Percent Day Covered (PDC) 80% is set as the cut-off for adherence.", 
                "measure": "Percentage of patients adherent to preventive medication: Beta-blocker", 
                "safety_issue": "No", 
                "time_frame": "16 months"
            }, 
            {
                "description": "As registered in the Electronic Health Record", 
                "measure": "Percentage of patients with Systolic Blood Pressure <140", 
                "safety_issue": "No", 
                "time_frame": "16 months"
            }, 
            {
                "description": "The Heart QoL instrument", 
                "measure": "Changes in Quality of Life", 
                "safety_issue": "No", 
                "time_frame": "16 months"
            }, 
            {
                "description": "According to the Health Care register of Kalmar County", 
                "measure": "Number of Cardiovascular Re-admissions and Emergency Department visits", 
                "safety_issue": "No", 
                "time_frame": "16 months"
            }, 
            {
                "description": "Quality adjusted life years estimated by the re-admissions and quality of Life using Euroqol EQ-5D-5L", 
                "measure": "Costs of intervention related to costs saved and Quality-adjusted Life years", 
                "safety_issue": "No", 
                "time_frame": "16 months"
            }
        ], 
        "source": "Linneaus University", 
        "sponsors": {
            "collaborator": {
                "agency": "The Kamprad Family Foundation for Entrepreneurship, Research and Charity", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "G\u00f6ran Petersson", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}